# Daily Biopharma Digest (2026-01-21 UTC)

Events shown: 36 (top 3 per ticker)

## ACRS

- **TOPLINE** | filingDate: 2026-01-06 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1557746/000110465926001076/acrs-20260106x8k.htm
  - snippet: tements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, potential changes to interim, topline and preliminary data as more subject data become available, the Company&…

## AQST

- **PDUFA** | filingDate: 2026-01-09 | conf: 0.89
  - doc: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000003/aqst-20260109.htm
  - snippet: n the pending NDA by the FDA and that the FDA&#8217;s review of the NDA is ongoing. The Company is working to understand and resolve the concerns of the FDA prior to the scheduled PDUFA goal date of January 31, 2026. The Company stated in the press release att…
- **NDA_BLA_SUBMISSION** | filingDate: 2026-01-09 | conf: 0.76
  - doc: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000003/aqst-20260109.htm
  - snippet: cing the receipt of a notice from the U.S. Food and Drug Administration (FDA) that, as part of its ongoing review, the FDA had identified deficiencies in the New Drug Application (NDA) submitted by the Company for its product candidate, Anaphylm&#8482; (epinep…

## ATRA

- **CRL** | filingDate: 2026-01-12 | conf: 0.93
  - doc: https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/d34257d8k.htm
  - snippet: 20;Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO &#8482; (tabelecleucel)&#8221; announcing that the&#160;U.S. Food and Drug Administration&#160;issued a Complete Response Letter for the EBVALLO &#8482; &#160;(tabelecleucel) Biologics…

## AXSM

- **NDA_BLA_SUBMISSION** | filingDate: 2025-12-31 | conf: 0.76
  - doc: https://www.sec.gov/Archives/edgar/data/1579428/000119312525337644/axsm-20251231.htm
  - snippet: tment of Alzheimer&#8217;s Disease Agitation. Also on December 31, 2025, the Company issued a press release announcing that it had received formal pre-New Drug Application (&#8220;NDA&#8221;) meeting minutes from the FDA for its planned NDA submission for AXS-…

## BBNX

- **TOPLINE** | filingDate: 2026-01-08 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1674632/000117184326000145/f8k_010726.htm
  - snippet: and Financial Condition. &#160; On January 8, 2026, Beta Bionics, Inc. (the &#8220;Company&#8221;) issued a press release announcing its preliminary, unaudited fourth quarter 2025 topline financial results and key metrics. A copy of the press release is attach…

## BIOA

- **TOPLINE** | filingDate: 2026-01-12 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1709941/000119312526009911/bioa-20260112.htm
  - snippet: h obesity and cardiovascular risk factors. The trial is planned to enroll approximately 100 patients randomized 1:1 to BGE-102 monotherapy or placebo for 12 weeks. The anticipated primary endpoint is percent change in hsCRP. The trial will also assess inflamma…

## CABA

- **NDA_BLA_SUBMISSION** | filingDate: 2026-01-12 | conf: 0.76
  - doc: https://www.sec.gov/Archives/edgar/data/1759138/000119312526009819/caba-20260112.htm
  - snippet: y 14 DM patients aligned with natural U.S. prevalence estimates. If successful, data from this cohort will support Cabaletta&#8217;s first projected Biologics License Application (BLA) submission for rese-cel in myositis next year. &#8226; FDA alignment on new…
- **TOPLINE** | filingDate: 2026-01-12 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1759138/000119312526009819/caba-20260112.htm
  - snippet: es affect approximately 70,000 patients in the U.S., with DM comprising approximately 60,000 patients. The registrational cohort is expected to evaluate 17 patients with a 16-week primary endpoint of moderate or major total improvement score response while off…

## CGEM

- **NDA_BLA_SUBMISSION** | filingDate: 2026-01-08 | conf: 0.73
  - doc: https://www.sec.gov/Archives/edgar/data/1789972/000119312526006998/cgem-20260108.htm
  - snippet: sion of a new drug application ("NDA") seeking accelerated approval of zipalertinib for the treatment of patients with relapsed EGFR ex20ins NSCLC. Taiho expects completion of the NDA submission in the first quarter of 2026. Taiho expects to complete enrollmen…

## CGON

- **TOPLINE** | filingDate: 2026-01-09 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1991792/000119312526008329/ck0001991792-20260109.htm
  - snippet: s are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the anticipated timeline of topline pivotal data of the PIVOT-006 study, the potential therapeutic benefits …

## CORT

- **CRL** | filingDate: 2025-12-31 | conf: 0.96
  - doc: https://www.sec.gov/Archives/edgar/data/1088856/000119312525338184/d50993d8k.htm
  - snippet: em&#8201;8.01. Other Events. On December&#160;31, 2025, Corcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for relacorilant as …

## COYA

- **TOPLINE** | filingDate: 2026-01-20 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1835022/000119312526016017/d48170d8k.htm
  - snippet: announced its cash balance as of December&#160;31, 2025 was $46.8&#160;million (unaudited) with projected cash runway into the second half of 2027, and that the Company expects a topline data readout from its current ALSTARS Phase 2 trial in the first quarter …

## CRNX

- **TOPLINE** | filingDate: 2026-01-05 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1658247/000119312526002368/d86003d8k.htm
  - snippet: Crinetics issued a press release and made available a corporate presentation (the &#8220;Presentation&#8221;) announcing certain updates regarding PALSONIFY commercialization and topline results from the fourth cohort of the Phase 2 trial of atumelnant for con…

## IDYA

- **TOPLINE** | filingDate: 2026-01-12 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1676725/000119312526009653/d93674d8k.htm
  - snippet: the intent-to-treat population enrolled in the Phase 2b/3 portion of the trial, which comprises approximately 313 patients randomized 2:1 to the treatment versus control arm. The topline PFS results, if positive, are anticipated to enable a potential accelerat…

## INBS

- **TOPLINE** | filingDate: 2026-01-08 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1725430/000149315226000984/form8-k.htm
  - snippet: closing bid price per share of the Company&#8217;s common stock was below $1.00 per share for 30 consecutive business days preceding the date of the Bid Price Notice, the Company did not meet the $1.00 per share minimum bid price requirement for continued incl…

## INO

- **PDUFA** | filingDate: 2025-12-29 | conf: 0.92
  - doc: https://www.sec.gov/Archives/edgar/data/1055726/000119312525332322/d78035d8k.htm
  - snippet: Company&#8217;s BLA for INO-3107 for review as a potential treatment for adults with RRP. The review classification designated by the FDA is Standard. The FDA assigned INO-3107 a Prescription Drug User Fee Act (PDUFA) review goal date of October&#160;30, 2026,…
- **ADCOM** | filingDate: 2025-12-29 | conf: 0.76
  - doc: https://www.sec.gov/Archives/edgar/data/1055726/000119312525332322/d78035d8k.htm
  - snippet: iew goal date of October&#160;30, 2026, which is the date by which it intends to take action on the application. The FDA has indicated that it is not currently planning to hold an advisory committee meeting to discuss this application. The Company filed the BL…

## IONS

- **TOPLINE** | filingDate: 2026-01-07 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/874015/000114036126000435/ef20062477_8k.htm
  - snippet: is associated with significant reduction in the risk of long-term liver complications, including liver cancer, as well as all-cause mortality. &#160; The B-Well studies met their primary endpoint, and bepirovirsen demonstrated a statistically significant and c…

## MBRX

- **TOPLINE** | filingDate: 2026-01-07 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1659617/000143774926000695/mbrx20260106_8k.htm
  - snippet: sting Rule 5550(b)(1) (the &#8220;Listing Rule&#8221;), which requires that the Company maintain a minimum of $2.5 million in stockholders&#8217; equity, and that the Company also did not meet the alternatives of market value of listed securities or net income…
- **TOPLINE** | filingDate: 2025-12-22 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1659617/000143774925038478/mbrx20251221_8k.htm
  - snippet: sting Rule 5550(b)(1) (the &#8220;Listing Rule&#8221;), which requires that the Company maintain a minimum of $2.5 million in stockholders&#8217; equity, and that the Company also did not meet the alternatives of market value of listed securities or net income…

## MLYS

- **TOPLINE** | filingDate: 2026-01-06 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000002/mlys-20260106.htm
  - snippet: sued a press release disclosing that it (i) filed a new drug application for lorundrostat to the U.S. Food and Drug Administration in late 2025 and (ii) remains on track to report topline results from its Phase 2 Explore-OSA trial, which is evaluating the safe…

## MPLT

- **TOPLINE** | filingDate: 2026-01-09 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1770069/000119312526008267/mplt-20260109.htm
  - snippet: in such a filing. Item 7.01 Regulation FD Disclosure. On January 9, 2026, the Company issued a press release announcing an update to its timing expectations for the disclosure of topline results from its ongoing Phase 2 ZEPHYR and IRIS clinical trials, which a…

## NTLA

- **CLINICAL_HOLD** | filingDate: 2026-01-09 | conf: 0.91
  - doc: https://www.sec.gov/Archives/edgar/data/1652130/000119312526008307/d15047d8k.htm
  - snippet: TTR-CM&#8221;). This case met the trial&#8217;s protocol-defined pausing criteria, and the United States Food and Drug Administration (the &#8220;FDA&#8221;) subsequently placed a clinical hold on the Investigational New Drug applications for the MAGNITUDE and…

## OTLK

- **CRL** | filingDate: 2026-01-02 | conf: 0.93
  - doc: https://www.sec.gov/Archives/edgar/data/1649989/000110465926000066/tm2534608d1_8k.htm
  - snippet: er Events. &#160; On December 31, 2025, Outlook Therapeutics, Inc (the &#8220;Company&#8221;) issued a press release announcing that the U.S. Food and Drug Administration issued a complete response letter to the Company&#8217;s biologics license application fo…

## PDSB

- **TOPLINE** | filingDate: 2026-01-09 | conf: 0.68
  - doc: https://www.sec.gov/Archives/edgar/data/1472091/000114036126000786/ef20062601_8k.htm
  - snippet: (the &#8220;FDA&#8221;) for its Phase 3 VERSATILE-003 clinical trial. The proposed amendment to the VERSATILE-003 Phase 3 trial changes the progression free survival endpoint to a primary endpoint that can be evaluated earlier with significant statistical powe…

## RARE

- **TOPLINE** | filingDate: 2025-12-29 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1515673/000119312525332422/rare-20251229.htm
  - snippet: improvements in BMD were associated with a reduction in annualized fracture rate for setrusumab treated patients compared to bisphosphonate treated patients, though the reduction did not meet statistical significance. The Company is conducting additional analy…

## RYTM

- **PDUFA** | filingDate: 2026-01-09 | conf: 0.86
  - doc: https://www.sec.gov/Archives/edgar/data/1649904/000162828026001459/rytm-20260109.htm
  - snippet: e Acquired Hypothalamic Obesity (HO) &#8226; Launch IMCIVREE in the United States for the treatment of acquired hypothalamic obesity pending FDA approval; the FDA&#8217;s assigned PDUFA goal date is March 20, 2026; &#8226; Announce topline data in the 12-patie…
- **TOPLINE** | filingDate: 2026-01-09 | conf: 0.71
  - doc: https://www.sec.gov/Archives/edgar/data/1649904/000162828026001459/rytm-20260109.htm
  - snippet: IMCIVREE in the United States for the treatment of acquired hypothalamic obesity pending FDA approval; the FDA&#8217;s assigned PDUFA goal date is March 20, 2026; &#8226; Announce topline data in the 12-patient Japanese cohort of the setmelanotide Phase 3 tria…

## STOK

- **NDA_BLA_SUBMISSION** | filingDate: 2026-01-12 | conf: 0.76
  - doc: https://www.sec.gov/Archives/edgar/data/1623526/000119312526009781/d36198d8k.htm
  - snippet: o support the submission of a New Drug Application (an &#8220;NDA&#8221;) to the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). The Company plans to initiate a rolling NDA submission in the first half of 2027. &#160; &#160; &#8226; &#160; The Compa…

## TOVX

- **TOPLINE** | filingDate: 2025-12-29 | conf: 0.68
  - doc: https://www.sec.gov/Archives/edgar/data/894158/000110465925124523/tm2534356d1_8k.htm
  - snippet: 1 plus gemcitabine/nab-paclitaxel SoC compared to gemcitabine/nab-paclitaxel SoC alone. The CHMP scientific advice included agreement on the proposed inclusion/exclusion criteria, primary endpoint (overall survival), secondary endpoints (including progression …

## TVTX

- **PDUFA** | filingDate: 2026-01-13 | conf: 0.89
  - doc: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000005/tvtx-20260113.htm
  - snippet: &#8220;sNDA&#8221;) for FILSPARI&#174; (sparsentan) in focal segmental glomerulosclerosis (&#8220;FSGS&#8221;). The new Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) target action date is April 13, 2026. The extension follows the recent submission of re…

## VTGN

- **TOPLINE** | filingDate: 2025-12-22 | conf: 0.68
  - doc: https://www.sec.gov/Archives/edgar/data/1411685/000162828025058594/vtgn-20251217.htm
  - snippet: en Therapeutics, Inc. (the " Company ") announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not achieve its primary endpoint, as measured by the least squares (" LS" ) mean change from bas…

## ZBIO

- **TOPLINE** | filingDate: 2026-01-05 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1953926/000110465926000402/tm261774d1_8k.htm
  - snippet: Agreement. &#160; The Company also expects to report the obexelimab 24-week Phase 2 MoonStone trial results in Relapsing Multiple Sclerosis later in the first quarter of 2026 and topline results, including a biomarker analysis, of the obexelimab Phase 2 SunSto…

## ZNTL

- **TOPLINE** | filingDate: 2026-01-09 | conf: 0.68
  - doc: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000003/zntl-20260106.htm
  - snippet: tory ASPENOVA Phase 3 trial initiation expected in first half of 2026. The planned Phase 3 trial is expected to be conducted concurrently with DENALI Part 2. &#8226; DENALI Part 2 topline readout on track and expected by year end 2026. DENALI Part 2, if succes…

## ZURA

- **TOPLINE** | filingDate: 2026-01-12 | conf: 0.65
  - doc: https://www.sec.gov/Archives/edgar/data/1855644/000110465926002688/tm262894d1_8k.htm
  - snippet: ny issued a press release announcing certain corporate and clinical trial updates&#8239;and its outlook for 2026, including updates on the Company&#8217;s cash runway and expected topline data readout timelines for its two ongoing Phase 2 clinical studies of t…
